Letrozole 2.5 mg

Adult dose

○ Adults and older adults: The recommended dose is 2.5 mg of letrozole orally once daily, with or without food. If you miss a dose, take it as soon as you remember. However, if it is nearly time for your next dose, skip the missed dose and continue with your regular schedule. Do not take a double dose to make up for a missed dose; do not exceed the recommended dose of 2.5 mg. In patients with metastatic disease, continue treatment until disease progression is confirmed. For adjuvant therapy and extended adjuvant therapy following adjuvant tamoxifen, treatment may be continued for 5 years. If cancer recurs during treatment, discontinue treatment (for extended adjuvant therapy following adjuvant tamoxifen, the optimal treatment duration associated with long-term use has not been established). ○ Patients with hepatic impairment: Blood concentrations of this medicine increase slightly in patients with moderate hepatic impairment due to cirrhosis, but no dose adjustment is required in patients with mild to moderate hepatic impairment. However, patients with severe hepatic impairment (Child-Pugh score C) should be under continuous and careful supervision when using this medicine. ○ Patients with renal impairment: No dose adjustment is required in patients with renal impairment and a creatinine clearance of 10 mL/min or higher.

This medication should not be used by individuals who are allergic to this drug or its components, premenopausal women, pregnant or potentially pregnant women, and breastfeeding women. Those with severely impaired renal function or significant liver dysfunction should use this medication with caution, and those with a history of osteoporosis or at high risk of fractures should have regular bone density tests and closely monitor their bone health. If menopause status is uncertain, hormone testing should be conducted to confirm menopausal status before taking this medication. This drug contains certain dye components, so care is needed for those who are allergic to these ingredients. While taking this medication, symptoms related to estrogen deficiency, such as facial flushing, arthralgia, nausea, and fatigue, may occur, and occasionally thrombosis, heart problems, liver function abnormalities, or skin adverse reactions may arise. Consult a physician immediately if abnormal symptoms occur. Due to the risk of osteoporosis and fractures, continuous monitoring of bone health is needed, and appropriate treatment should be sought if necessary. This medication is metabolized in the liver, so caution is required for patients with impaired liver function or those taking other drugs that affect certain liver enzymes due to potential drug interactions. Pregnant women or those planning pregnancy should not take this medication, and premenopausal women should employ adequate contraception. The safety and efficacy of this medication have not been established in children under 17 years of age. There is no need for special dosage adjustments in the elderly, but caution is warranted due to the higher risk of fractures. In case of overdose, there are no specific antidotes, and appropriate treatment and observation based on symptoms are necessary. This medication should be stored out of reach of children and kept in its original container to prevent misuse or deterioration in quality. Caution is required during driving or operating machinery as fatigue or dizziness may occur.

• Urinary tract infection
• pain from mass
• leukopenia
• anaphylactic reaction
• hypercholesterolemia
• loss of appetite
• increased appetite
• depression
• anxiety
• irritability

This medication is sensitive to air and moisture, so it must be stored in a tightly sealed container. It should also be kept in a cool place below 30 degrees Celsius to maintain its effectiveness.

Appearance

Dark yellow, round film-coated tablets

Package unit

30 tablets/box [10 tablets/PTP×3]